Dementia 2024 | Dementia Conferences | Neurological Disorder Congress | Parkinson Disease Event | Barcelona | Spain

Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academies Conferences

Theme

"Mind Over Matter: A Journey of Mental Strength in the Face of Dementia and Alzheimer's Conflicts"

- Dementia 2024

Welcome Message

Dear Colleagues and Participants,

With great pleasure and anticipation, we extend a heartfelt welcome to the esteemed attendees of the 16th International Conference on Dementia and Alzheimer's Disease, set to unfold its chapters of knowledge on May 09-10, 2024, in the enchanting city of Barcelona, Spain.

The Dementia and Alzheimer's Conferences have evolved into a beacon of excellence, serving as a pivotal hub for the global community dedicated to unraveling the complexities of neurodegenerative disorders. Our commitment to advancing the frontiers of knowledge is mirrored in the caliber of nearly 70 distinguished speakers and moderators, drawn from diverse institutions spanning the globe. The virtual assembly in May 2023 witnessed the participation of 300-400 registrants, while the February 2022 event gathered a substantial audience of 700-600 registrants, reinforcing the significance of this shared pursuit.

Over the course of three enlightening days, our in-person conference promises a profound exploration into the nuances of dementia and Alzheimer's research. From foundational principles to groundbreaking discoveries, our agenda is curated to foster an academic exchange that transcends disciplinary boundaries.

This year's conference is distinguished not only by its exceptional content but by the physical presence of a renowned cadre of national and international faculty. These luminaries, leaders in their respective domains, will guide us through a stimulating intellectual journey.

As the organizing team behind the Dementia and Alzheimer's Conferences 2024, we invite you to immerse yourself in this unparalleled experience. Expect a day filled with collaborative discourse, innovative insights, and networking opportunities that extend beyond the confines of the conference halls.

We look forward to your presence at what promises to be a landmark event in the pursuit of understanding and combating dementia and Alzheimer's disease.

Best Regards,
Catalina Cameron
Program Manager
E: [email protected]

About

This two-day conference on Dementia and Alzheimer's is tailored explicitly for healthcare professionals dedicated to advancing the understanding and treatment of neurodegenerative disorders. Our primary objective is to furnish practitioners with a comprehensive update on the latest developments in dementia and Alzheimer's research, with a specific emphasis on cutting-edge approaches and pediatric considerations.

The overarching theme, "Mind Over Matter: A Journey of Mental Strength in the Face of Dementia and Alzheimer's Conflicts," underscores our commitment to relevance and the global impact of this conference.

The focus of the conference will revolve around precision approaches to the Prevention, Diagnosis, Treatment, Prognosis, and Monitoring of Dementia and Alzheimer's conditions and disorders.

The conference program includes Keynote Lectures, Panel Discussions, Video Sessions, Instructional Sessions, and Poster Presentations. By offering both in-person and virtual participation through the Webex platform, this event aims to unite scientists and clinicians from across the world. This hybrid format allows for the exchange of experiences, the generation of new ideas, the fostering of friendships, and the formation of collaborations.

Format of the Conference: The Dementia and Alzheimer's Conference 2024 will be hosted both in-person in the vibrant city of Barcelona, Spain, and virtually through the Webex platform with on-demand sessions. Whether you join remotely from your home or office or attend in person, the recordings will be available after the conference. This ensures that even if you miss any lectures, you can catch up by watching the recordings later. Access to all lecture videos and handouts will be available for six months following the conference.

Learning Objectives:

Apply state-of-the-art treatment modalities and therapies in the field of Dementia and Alzheimer's.
Incorporate current evidence-based research into the treatment of neurodegenerative disorders.
Stay updated on practical applications influencing operative procedures, pharmaceuticals, and medical devices.
Understand the latest evidence-based clinical pathways and best practices.
Review patient outcomes based on peer-reviewed research.

Who Should Attend?

Neurologists
Geriatricians
Psychiatrists
Researchers in Neuroscience
Nurses specializing in Neurological Care
Public Health Professionals

What's New?

Dedicated tracks for Advanced Neuroimaging, Therapeutic Approaches, and Pediatric Neurology.
Hands-on training workshops featuring international experts in Dementia and Alzheimer's research.
Over 50 scientific poster presentations showcasing the latest research findings.
More international guest speakers from the USA, Canada, Australia, Europe, Asia, and the GCC region.

We look forward to welcoming you to the 16th International Conference on Dementia and Alzheimer's Disease, fostering collaboration, and advancing our collective understanding of these critical neurological challenges.

Best Regards,
Catalina Cameron
Program Manager
E: [email protected]

Market Analysis

Global Dementia and Alzheimer's Market Analysis:

The global Dementia and Alzheimer's market recorded a significant valuation of USD 21.9 billion in 2021, projecting a robust compound annual growth rate (CAGR) of 5.69% from 2022 to 2030. The market's upward trajectory is fueled by an increasing adoption of minimally invasive procedures, a surge in the prevalence of neurodegenerative disorders, and the aging global population. Technological advancements are playing a pivotal role in propelling this growth.

The demand for advanced dementia and Alzheimer's devices, including those incorporating innovative technologies such as AI and machine learning, is on the rise. In developing economies, the utilization of such devices has been limited due to their high costs; however, efforts to improve healthcare access and rising healthcare spending are expected to drive market penetration in these regions.

Key Trends:

Rising Prevalence of Hearing Loss: Hearing impairment has become a widespread medical concern, affecting over 460 million people globally. The World Health Organization predicts that this number will surpass 900 million by 2050, primarily due to increased life expectancy and higher noise pollution levels.
Technological Advancements: The industry is witnessing a surge in technological advancements, including the integration of AI and machine learning. Companies like Audibel and Lively are introducing cutting-edge products such as AI hearing aids, showcasing the industry's commitment to innovation.

Market Dynamics:

Market Size: The global Dementia and Alzheimer's market, valued at USD 21.9 billion in 2021, is anticipated to grow at a CAGR of 5.69% from 2022 to 2030.
Product Segmentation: The market is categorized into diagnostic devices, surgical devices, hearing image-guided surgery systems, and others. Notably, home-use devices and ambulatory surgical centers are expected to witness significant growth.

Continent-wise Dementia and Alzheimer's Market Analysis:

North America: Leading the market in 2021 with a 32.8% revenue share, North America benefits from an improving reimbursement scenario, strong market players, and increased awareness of ENT devices.
Asia Pacific (APAC): Anticipated to experience rapid growth, particularly in China and India, due to a large patient pool with sinusitis, heightened device awareness, and an aging population.
Europe: Accounting for the second-largest revenue share in 2021, Europe boasts high product penetration for hearing aids, driven by a well-established healthcare infrastructure.
Africa: The smallest region in the global ENT market, Africa demonstrates potential for growth with increasing healthcare awareness.

Key Players in the Dementia and Alzheimer's Market:

Cochlear Ltd.
Starkey Laboratories, Inc.
Rion Co., Ltd.
Demant A/S
Sonova
GN Store Nord A/S
Pentax Medical
Karl Storz
Olympus Corporation
Richard Wolf GmbH

Spain Market Analysis:

The Otolaryngology Devices Market in Spain is a dynamic landscape, with significant contributions to the global Dementia and Alzheimer's market. The market outlook to 2025 reveals insights into diagnostic devices, hearing aid devices, hearing implants, nasal splints, and speech aid devices.

Major Players in Spain:
- William Demant Holding A/S
- Natus Medical Incorporated
- Hill-Rom Holdings Inc.

Sessions

Alzheimers Diseases
Dementia
Molecular Genetics and Biology of Dementia
Cognitive Therapies of Dementia
Types of Dementia
Vascular and Lewy Body Dementia
Parkinson and Huntington Dementia
Geriatrics and Semantic Dementia
Dementia Nursing
Neurology, Neurosurgery & Psychiatry
Neuroimaging and Neurological Disorder
Neuropharmacology and Neurodegenerative Diseases
Pediatric Neurology & Psychiatry
Early and Younger onset of Dementia and Alzheimer Diseases
Amyloid Protein in Dementia
Bioinformatics Approach for Dementia and Alzheimer Diseases
Drug Development in Dementia
Animal Model and Translational Medicines
Novel Therapeutics Targets and Mechanism for Treatments
Causes, Symptoms of Alzheimer and Dementia
Prevention Measures
Care Practice and Awareness
Clinical Trials and Case Reports
Current Research in Therapeutic Targets

Alzheimers Diseases

Alzheimer's disease, a progressive neurodegenerative condition, affects millions globally, casting a shadow over their lives. Marked by memory loss, cognitive decline, and behavioral changes, Alzheimer's strips individuals of independence and disrupts the fabric of their existence. Despite notable progress in research, the fundamental mechanisms of Alzheimer's remain unclear, and finding successful treatments remains a challenge. Let us join forces to unravel the mysteries of Alzheimer's, create effective therapies, and bring hope back to those impacted by this devastating ailment. May 2024 be a pivotal moment in our united efforts against Alzheimer's.

Related Conferences

Related Societies

Related Journals Associations

Nordic Association of Dementia and Alzheimer's Research | American Dementia Association | American Academy of Alzheimer's Research | American Academy of Dementia and Neurology | Brazilian Association of Dementia and Cognitive Health | Association for Research in Dementia Conferences | Emirates Association of Alzheimer's Research

Related Journals

Journal of Dementia and Alzheimer's Research | Journal of Neurology and Cognitive Science | Journal of Geriatric Psychiatry and Neurology | International Journal of Alzheimer's Disease | American Journal of Geriatric Psychiatry | Australian Journal of Cognitive Neuroscience Conferences | Dementia National Journal | Impact Factor rank of Dementia and Alzheimer's Conferences Journals

Dementia

Dementia, an extensive term covering various cognitive impairments, impacts millions of individuals globally. It is characterized by a reduction in memory, cognitive functions, and behavioral capabilities that disrupt daily activities. While Alzheimer's disease stands as the most prevalent cause of dementia, other factors like vascular disease, Lewy body dementia, and frontotemporal dementia can also play a role in cognitive decline.

The Alzheimer's 2024 conference is set to include a scientific segment specifically focused on dementia. This session will showcase the latest research on the origins, symptoms, and potential treatments of dementia. It aims to delve into the multifaceted factors contributing to dementia, along with emerging approaches for prevention, diagnosis, and care.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Molecular Genetics and Biology of Dementia

Dementia refers to a significant decline in mental capacity that hinders daily functioning. While memory loss is a prominent symptom, it can also impact other cognitive abilities like language, problem-solving, and perception. The root cause of dementia lies in damage to brain cells, with Alzheimer's disease being the predominant factor, responsible for 60 to 80 percent of cases.

The Alzheimers 2024 initiative serves as a crucial platform for researchers, clinicians, and advocates to join forces against dementia. Through promoting collaboration and disseminating state-of-the-art findings, we aim to expedite the pace of discovery and pave the way for a future devoid of dementia.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Cognitive Therapies of Dementia

Cognitive therapies have emerged as promising strategies for addressing dementia symptoms by enhancing neural connections and promoting neuroplasticity, the brain's capacity to adapt and learn.

Reality orientation, a widely utilized cognitive therapy, focuses on providing consistent information about time, place, and person to help individuals with dementia maintain a connection with reality. Cognitive stimulation therapy involves engaging in mentally stimulating activities like puzzles, games, and discussions to enhance cognitive function.

The Alzheimer's 2024 conference will include a scientific session dedicated to cognitive therapies for dementia, featuring the latest research on their effectiveness and potential advantages. Experts will share findings from clinical trials assessing various cognitive therapy approaches and discuss their role in enhancing the quality of life for individuals affected by dementia.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Types of Dementia

Dementia, a comprehensive term encompassing various neurodegenerative conditions, disrupts lives and erodes memories. Marked by a gradual decline in cognitive functions, dementia presents itself in different forms, each with distinct characteristics and challenges.

Alzheimer's disease, the predominant form of dementia, is identified by the build-up of amyloid plaques and tau tangles in the brain. Vascular dementia, often linked to stroke or cardiovascular issues, results from compromised blood flow to the brain. Lewy body dementia is distinguished by the presence of abnormal protein deposits known as Lewy bodies in the brain. Frontotemporal dementia,

Accurate diagnosis and effective management of dementia hinge on understanding its diverse types. Alzheimers 2024 invites you to explore the intricacies of dementia and discover the latest developments in diagnosis and treatment. Join us in unraveling the spectrum of dementia, providing empowerment to individuals and families navigating this challenging condition.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Vascular and Lewy Body Dementia

Vascular dementia stands as the second most prevalent cause of dementia, following Alzheimer's disease. It results from damage to the brain's blood vessels, disrupting the supply of blood and oxygen to brain cells. Symptoms of vascular dementia can vary based on the location and severity of the damage, encompassing issues like memory loss, cognitive difficulties, and movement problems.

Lewy body dementia, the third most common cause of dementia, is characterized by abnormal protein deposits called Lewy bodies in the brain. These deposits can disrupt communication pathways in the brain, leading to a range of symptoms, including cognitive decline, visual hallucinations, and movement issues.

Alzheimers 2024, an international conference, serves as a gathering for researchers, clinicians, and patient advocates to explore the latest advancements in dementia research and care. The conference facilitates the exchange of knowledge and collaboration on innovative approaches to prevent, treat, and ultimately find a cure for dementia.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Parkinson and Huntington Dementia

Dementia in Parkinson's disease is marked by cognitive deterioration in memory, executive function, and visuospatial abilities. Its presence indicates a faster disease progression and heightened mortality. Ongoing research is concentrated on pinpointing biomarkers for early Parkinson's dementia detection and creating targeted therapies to impede or delay cognitive decline.

In Huntington's disease, dementia involves cognitive regression in executive function, language, and behavior. Its presence correlates with a more pronounced motor phenotype and increased disability. Current research is directed towards comprehending the role of the huntingtin protein in cognitive decline and formulating neuroprotective therapies to decelerate the progression of Huntington's dementia.

The upcoming Alzheimer's 2024 conference is poised to be a significant milestone in neurodegenerative dementia research, offering fresh insights and optimism for enhanced diagnosis, treatment, and prevention of both Parkinson's and Huntington's dementia.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Geriatrics and Semantic Dementia

Dementia associated with Parkinson's disease is characterized by a decline in cognitive functions such as memory, executive function, and visuospatial abilities. The presence of dementia in Parkinson's is linked to a more rapid progression of the disease and increased mortality. Current research is dedicated to identifying biomarkers for the early detection of Parkinson's dementia and developing targeted therapies to prevent or slow down cognitive decline.

In the case of Huntington's disease, dementia is marked by a decline in executive function, language, and behavior. The presence of dementia in Huntington's is associated with a more severe motor phenotype and increased disability. Ongoing research is focused on understanding the role of the huntingtin protein in cognitive decline and devising neuroprotective therapies to mitigate the progression of Huntington's dementia.

The Alzheimer's 2024 conference is anticipated to be a pivotal event in the realm of neurodegenerative dementia research, offering fresh perspectives and optimism for advancements in the diagnosis, treatment, and prevention of both Parkinson's and Huntington's dementia.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Dementia Nursing

Specializing in the care of individuals with dementia, including Alzheimer's disease, dementia nursing is a distinct field that concentrates on delivering comprehensive support. Nurses assume a crucial role in addressing the intricate symptoms and difficulties linked to dementia, aiming to enhance the well-being and quality of life for both patients and their families.

The forthcoming Alzheimer's 2024 conference will feature a significant focus on dementia nursing, shedding light on recent progress and effective approaches in dementia care. Nurses will engage in discussions to exchange insights, share their expertise, and glean valuable knowledge to improve the provision of optimal care for individuals coping with dementia.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Neurology, Neurosurgery & Psychiatry

Neurology and neurosurgery represent closely intertwined medical specialties devoted to diagnosing, treating, and preventing disorders of the nervous system. Neurology primarily focuses on non-surgical interventions, while neurosurgery involves surgical procedures to address conditions impacting the brain, spinal cord, and peripheral nerves.

The imminent Alzheimer's 2024 conference will convene experts from both disciplines to explore the latest advancements in research and treatment for Alzheimer's disease. Discussion topics may encompass:

The influence of genetics and lifestyle on Alzheimer's disease Novel diagnostic tools and biomarkers facilitating early detection Emerging therapies designed to slow or prevent disease progression The significance of patient-centered care and engagement in clinical trials. Anticipated to offer valuable insights, the conference is poised to benefit researchers, clinicians, and those affected by Alzheimer's disease.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Neuroimaging and Neurological Disorder

Neuroimaging has transformed our comprehension of neurological disorders, providing a glimpse into the intricate workings of the brain. From Alzheimer's to Parkinson's, advanced neuroimaging methods such as MRI, PET, and SPECT have empowered us to observe brain structure, function, and metabolism, furnishing valuable insights into the development of diseases and the response to treatment.

The forthcoming Alzheimer's 2024 conference will feature the latest breakthroughs in neuroimaging, emphasizing its pivotal role in Alzheimer's research. Experts will delve into the utilization of neuroimaging to pinpoint early biomarkers of Alzheimer's, monitor disease progression, and assess the effectiveness of novel treatments.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Neuropharmacology and Neurodegenerative Diseases

The intricate connection between neuropharmacology and neurodegenerative diseases is becoming increasingly apparent as research delves deeper into the intricacies of the nervous system. With the approach of Alzheimer's 2024, the upcoming scientific session on this topic holds great promise for revealing innovative therapeutic approaches and gaining insights into the fundamental mechanisms contributing to neurodegeneration.

Central to this discourse is the exploration of pharmacological agents targeting specific molecular pathways associated with Alzheimer's disease. The development of drugs that influence neurotransmitter systems, regulate protein aggregation, and enhance neuroprotective mechanisms carries the potential to arrest or even reverse the progression of this devastating disorder.

The scientific session on neuropharmacology and neurodegenerative diseases at Alzheimer's 2024 is set to be a crucial platform for exchanging groundbreaking discoveries, fostering collaborations, and propelling progress towards effective treatments for Alzheimer's disease and other neurodegenerative conditions.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Pediatric Neurology & Psychiatry

The intricate interplay between neuropharmacology and neurodegenerative disorders has become increasingly apparent as research dives into the complexities of the nervous system. Approaching Alzheimer's 2024, the imminent scientific session on this topic holds significant promise for unveiling innovative therapeutic strategies and gaining a deeper understanding of the fundamental mechanisms contributing to neurodegeneration.

At the forefront of this discourse is the investigation of pharmacological agents designed to target specific molecular pathways implicated in Alzheimer's disease. The development of drugs that modulate neurotransmitter systems, regulate protein aggregation, and enhance neuroprotective mechanisms offers the potential to arrest or even reverse the progression of this debilitating disorder.

The scientific session on neuropharmacology and neurodegenerative diseases at Alzheimer's 2024 is poised to be a pivotal platform for the exchange of cutting-edge findings, the cultivation of collaborations, and the acceleration of efforts toward effective treatments for Alzheimer's disease and other neurodegenerative conditions.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Early and Younger onset of Dementia and Alzheimer Diseases

The intricate interconnection between neuropharmacology and neurodegenerative diseases is becoming increasingly evident as research delves deeper into the intricacies of the nervous system. With the approach of Alzheimer's 2024, the upcoming scientific session on this subject holds great potential for uncovering innovative therapeutic strategies and gaining a deeper comprehension of the underlying mechanisms contributing to neurodegeneration.

Central to this discourse is the exploration of pharmacological agents targeting specific molecular pathways associated with Alzheimer's disease. The development of drugs that modulate neurotransmitter systems, regulate protein aggregation, and enhance neuroprotective mechanisms represents a promising avenue for potentially halting or reversing the progression of this debilitating disorder.

The scientific session on neuropharmacology and neurodegenerative diseases at Alzheimer's 2024 is anticipated to serve as a crucial platform for the exchange of groundbreaking discoveries, the cultivation of collaborations, and the advancement of efforts towards effective treatments for Alzheimer's disease and other neurodegenerative conditions.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Amyloid Protein in Dementia

The pathogenesis of dementia, particularly Alzheimer's disease, is significantly influenced by the central involvement of the amyloid beta (Aβ) protein. Aβ is a naturally occurring fragment derived from the larger amyloid precursor protein (APP). In individuals without cognitive disorders, mechanisms like enzymatic degradation and transport across the blood-brain barrier work to clear Aβ from the brain. However, in those with dementia, Aβ accumulates and forms insoluble plaques in the brain, disrupting neuronal communication and contributing to cognitive decline.

The upcoming Alzheimer's 2024 conference will include a dedicated scientific session on the amyloid beta protein in dementia. This session will delve into the latest research regarding its role in the development of the disease, potential therapeutic targets, and innovative biomarkers for early diagnosis. Experts will explore the mechanisms underlying the accumulation of Aβ and its impact on brain function, presenting findings from clinical trials that investigate anti-amyloid therapies and their potential to alter the progression of the disease.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Bioinformatics Approach for Dementia and Alzheimer Diseases

In the field of dementia and Alzheimer's research, bioinformatics has emerged as a potent tool, providing a comprehensive approach to understanding and addressing these intricate neurodegenerative disorders. A dedicated scientific session at the upcoming Alzheimer's 2024 conference will explore the transformative applications of bioinformatics in this domain.

Bioinformatics utilizes computational methods to analyze extensive biological data, including genetics, gene expression, protein interactions, and imaging data. Through the integration of these diverse datasets, researchers can acquire valuable insights into the molecular foundations of dementia and Alzheimer's, identifying potential biomarkers, drug targets, and therapeutic approaches.

This scientific session will present the latest developments in bioinformatics-driven research on dementia, showcasing its role in deciphering the complex mechanisms of disease progression, enabling early diagnosis, and laying the groundwork for personalized treatment interventions. Experts will share their pioneering research, illustrating the profound impact of bioinformatics on the future of dementia care.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Drug Development in Dementia

The session will explore a variety of strategies in drug development, including small molecules, antibodies, and antisense oligonucleotides. Experts will discuss the targeting of crucial pathological features like amyloid plaques and tau tangles, along with emerging approaches focusing on neuroinflammation, synaptic dysfunction, and neuroprotective mechanisms.

A significant aspect of the session will concentrate on the design and execution of clinical trials, emphasizing the necessity for creative approaches to surmount obstacles that have hindered previous drug development endeavors in dementia. Researchers will share their insights on optimizing patient selection, utilizing biomarkers, and integrating cognitive and functional endpoints to evaluate treatment effectiveness.

The scientific session on drug development for dementia aims to provide a comprehensive overview of the current landscape in the field, emphasizing the potential of innovative therapeutic approaches and addressing challenges that must be tackled to translate scientific advancements into effective treatments for patients.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Animal Model and Translational Medicines

Carefully designed animal models, created to replicate the pathological features and cognitive deficits observed in dementia, represent invaluable tools for comprehending disease mechanisms and evaluating potential treatments. This session will highlight recent progress in the development of animal models, with a focus on models that more accurately mimic the human condition. This allows researchers to gain deeper insights into the progression of the disease and the effectiveness of treatments.

Animal models have been instrumental in advancing our knowledge of Alzheimer's disease and supporting the exploration of potential therapies. The forthcoming Alzheimer's 2024 conference will feature a specialized scientific session dedicated to delving into the complexities of animal models and their relevance in translational Alzheimer's research.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Novel Therapeutics Targets and Mechanism for Treatments

The session will examine a wide range of innovative therapeutic targets, including proteins, signaling pathways, and cellular processes that play a crucial role in the pathology of Alzheimer's disease. Experts will present their pioneering research on addressing neuroinflammation, synaptic dysfunction, and neuroprotective mechanisms, providing new perspectives on potential treatment approaches.

A key emphasis of the session will be on unraveling the underlying mechanisms of action of these novel therapeutic targets, enhancing our understanding of how these strategies can effectively combat Alzheimer's disease. Researchers will share their insights into the molecular and cellular processes contributing to disease progression, underscoring the potential of these novel approaches to arrest or even reverse the neurodegenerative processes associated with Alzheimer's.

The forthcoming Alzheimer's 2024 conference will feature a dedicated scientific session exploring the latest advancements in this field, showcasing promising therapeutic strategies that challenge traditional approaches and hold the potential to transform Alzheimer's care.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Causes, Symptoms of Alzheimer and Dementia

Alzheimer's disease and dementia are intricate neurological disorders affecting millions globally. Despite the elusive nature of their exact causes, ongoing research is enhancing our understanding of potential contributing factors. A significant factor associated with Alzheimer's disease is the accumulation of amyloid plaques and tau tangles in the brain, disrupting neural communication and leading to progressive cognitive decline. Additionally, genetic predispositions, environmental exposures, and lifestyle factors contribute to the development of Alzheimer's.

Dementia, a more encompassing term covering various cognitive impairments, includes Alzheimer's disease and other conditions affecting memory, thinking, and behavior. Common symptoms involve memory loss, language difficulties, problem-solving challenges, and alterations in personality and mood.

The upcoming conference is anticipated to assemble leading experts to explore the latest research on the causes, symptoms, and potential treatments for Alzheimer's disease and dementia. This scientific session aims to provide valuable insights into these challenging disorders and contribute to the ongoing efforts to identify effective interventions.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Prevention Measures

The session will delve into the potential of using pharmacological interventions to prevent Alzheimer's disease, assessing the evidence for repurposing existing medications or creating new drugs that target specific disease mechanisms. Researchers will address the challenges and prospects in this domain, underscoring the necessity for more rigorous research and clinical trials.

The scientific session on preventive measures for Alzheimer's disease aims to offer a comprehensive overview of the current knowledge, highlighting the significance of adopting a multifaceted approach. This approach integrates lifestyle modifications, cognitive interventions, and potentially pharmacological strategies to diminish the risk of developing Alzheimer's disease and enhance cognitive health throughout one's life.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Care Practice and Awareness

Alzheimer's disease is a progressive neurodegenerative condition that impairs memory and cognitive abilities, ultimately affecting the ability to perform everyday tasks. While there is no cure for Alzheimer's, various treatments exist to manage symptoms and slow down the progression of the disease.

In Alzheimer's 2024, a specialized scientific session will delve into recent developments in care practices and awareness surrounding Alzheimer's disease. Experts will emphasize the significance of early diagnosis and intervention, highlighting the necessity for holistic care that encompasses the physical, emotional, and social needs of individuals with Alzheimer's and their caregivers.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Clinical Trials and Case Reports

Clinical trials and case reports are pivotal in advancing our comprehension of Alzheimer's disease and formulating effective treatments. In the upcoming Alzheimer's 2024 conference, a specialized scientific session will explore recent progress in the design and methodology of clinical trials, underscoring the significance of case reports in elucidating rare and atypical presentations of Alzheimer's disease.

This session will delve into the challenges and opportunities inherent in the design and execution of clinical trials for Alzheimer's, emphasizing the necessity for innovative approaches in patient selection, outcome measures, and data analysis. Experts will discuss the latest developments in biomarker research and its potential to enhance the design and outcomes of clinical trials.

While case reports are sometimes considered anecdotal, they offer valuable insights into the diverse clinical manifestations of Alzheimer's disease and can guide future research. The session will underscore the importance of well-documented case reports and explore strategies to enhance their rigor and impact.

The scientific session on clinical trials and case reports aims to provide a comprehensive overview of the current state of the field, emphasizing the critical role of robust clinical trials and insightful case reports in advancing our understanding and treatment of Alzheimer's disease.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Current Research in Therapeutic Targets

The unwavering quest for effective treatments for Alzheimer's disease has resulted in the identification of numerous therapeutic targets, each with the potential to stop or reverse the neurodegenerative processes linked to this devastating disorder. In the upcoming Alzheimer's 2024 conference, a dedicated scientific session will delve into the latest research on therapeutic targets, presenting promising strategies that challenge conventional approaches and bring renewed hope to individuals affected by Alzheimer's disease.

This session will explore a varied range of therapeutic targets, including proteins, signaling pathways, and cellular processes crucial in Alzheimer's disease pathology. Experts will share their pioneering research on addressing neuroinflammation, synaptic dysfunction, and neuroprotective mechanisms, providing fresh insights into potential treatment approaches.

Related Conferences

Related Societies

Related Journals Associations

Related Journals

Organizing committee members

Dr. Lin Zhang, MD

Professor, Brain

Deep Brain Stimulation Program UC Davis Health System, USA

George N. Shilau

Republican Clinic Medical Center, Russia

Dr. Santiago Restrepo

American University Corporation, Colombia

Dr. Azza A Ali

Al Azhar University, Palestine

Dr. Hans von Holst

Karolinska Institute, Sweden

To Collaborate Scientific Professionals around the World

Conference Date	July 09-10, 2024
Poster Oppurtunity	Available
e-Poster Oppurtunity	Available

Testimonials

Dr. Shatrova Vera

LLC Merz Pharma, Russia

I am honoured to have been a part of this conference today and to have had the opportunity to share my thoughts and experiences with all of you. The past few days have been an incredible learning experience for me. Thank you!